Analyst Targets 200% Upside for This Biopharm

AZRX has been in a downtrend since going public in late 2016

Karee Venema

Feb 14, 2019 at 11:01 AM

AZRX

AzurRx BioPharma Inc (NASDAQ:AZRX) is a development stage biopharmaceutical firm whose two pipeline products are being developed to treat exocrine pancreatic insufficiency and c. difficile infections. Optimism around the former drug sparked this morning's bull note from Maxim, with the analyst in coverage initiating coverage on AZRX stock with a "buy" rating and $5 price target -- a 191% premium to last night's close.

This upbeat outlook just echoes the withstanding sentiment seen among the brokerage bunch, with all four covering analysts maintaining a "buy" or better rating. Plus, the average 12-month price target of $7.38 stands at a 321.7% premium to current trading levels.

Looking at the charts, AZRX hasn't traded above $5 since September 2017, and the shares have yet to see the north side of $7.38. Since going public in October 2016, the stock has been trending lower, culminating in a Dec. 27 record low of $1.00.

AzurRx BioPharma took a sharp bounce from here, but was swiftly rejected by its 200-day moving average in late January -- a trendline that's kept a tight lid on the shares over the last six months. The stock has shed 30% since this unsuccessful test, but remains 44.6% higher year-to-date -- up 2% today at $1.75.

azrx stock daily chart feb 14

Follow @Schaeffers

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released!